Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLS-A2
- Development stage
- Preclinical
- Lead developer
- Cellus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
CLS-A2 is a preclinical-stage bispecific monoclonal antibody developed by Cellus for the treatment of bone metastatic cancer. It is designed to simultaneously target C-X-C motif chemokine ligand 16 (CXCL16) and tumor necrosis factor ligand superfamily member 11 (TNFSF11, also known as RANKL). CXCL16 is a chemokine secreted by tumors that recruits immunosuppressive myeloid cells and stimulates RANKL expression, while RANKL is a key driver of osteoclast differentiation and bone resorption. By dual-targeting both CXCL16 and RANKL, CLS-A2 aims to inhibit bone destruction and remodel the immunosuppressive tumor microenvironment to overcome immunotherapy resistance in bone metastases.
02
Targets
CXCL16 (C-X-C motif chemokine ligand 16)RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)
Beyond the preview
Go deeper on CLS-A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLS-A2.